title: Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.
abstract: Replication-defective chimpanzee adenovirus vectors are emerging as a promising new class of genetic vaccine carriers. Chimpanzee adenovirus vectors have now reached the clinical stage and appear to be endowed with all the properties needed for human vaccine development, including high quality and magnitude of the immune response induced against the encoded antigens, good safety and ease of manufacturing on a large-scale basis. Here the authors review the recent findings of this novel class of adenovirus vectors and compare their properties to other clinical stage vaccine vectors derived from poxvirus, alphavirus and human adenovirus.
authors.affiliation: Okairos, viale Citta' d'Europa 679, 00144, Rome, Italy.
authors.forename: Stefania
authors.initials: S
authors.lastname: Capone
authors.forename: Anna Morena
authors.initials: AM
authors.lastname: D'Alise
authors.forename: Virginia
authors.initials: V
authors.lastname: Ammendola
authors.forename: Stefano
authors.initials: S
authors.lastname: Colloca
authors.forename: Riccardo
authors.initials: R
authors.lastname: Cortese
authors.forename: Alfredo
authors.initials: A
authors.lastname: Nicosia
authors.forename: Antonella
authors.initials: A
authors.lastname: Folgori
mesh_terms: D000261:Adenoviruses, Simian / Q000235:genetics*; D000818:Animals; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology; D004337:Drug Carriers; D016503:Drug Delivery Systems; D055808:Drug Discovery / Q000639:trends; D006801:Humans; D017780:Malaria Vaccines / Q000235:genetics / Q000276:immunology; D014611:Vaccination / Q000379:methods*; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology
chemical_list: D019496:Cancer Vaccines; D004337:Drug Carriers; D017780:Malaria Vaccines; D014765:Viral Vaccines